4s3 Bioscience Lands $20 Million in Venture Funding
3/5/2012 8:55:47 AM
Medford-based 4s3 Bioscience, Inc., a privately held biotech company focused on genetic disease therapies for orphan neuromuscular disorders, has secured $20 million in Series A funding with KLP Enterprises. KLP’s subsidiary, Alopexx Enterprises, a health-care company that invests and develops preclinical and early clinical compounds, will work with 4s3 to build and manage the company. The funding will go toward the continued development of an antibody technology that provides intracellular delivery of active proteins, enzymes and other macromolecules to skeletal muscles.